Terms ending in 2036
Every in-force patent on Adimab, LLC's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,308,718 | Anti-Sortilin Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | |
| US 11,208,488 | Methods of Increasing Progranulin Levels Using Anti-Sortilin Antibodies In force · High confidence | Alector LLC | In force | High confidence | |
| US 11,339,223 | Methods of Use of Anti-Sortilin Antibodies for Treating a Disease, Disorder, or Injury In force · High confidence | Alector LLC | In force | High confidence | |
| US 11,186,645 | Isolated Nucleic Acids Encoding Anti-Sortilin Antibodies In force · High confidence | Alector LLC | In force | High confidence | |
| US 11,746,160 | Antibodies Against BACE1 and Use Thereof for Neural Disease Immunotherapy In force · High confidence | Adimab LLC | In force | High confidence | |
| US 10,787,500 | Methods for Purifying Heterodimeric Multispecific Antibodies from Parental Homodimeric Antibody Species In force · High confidence | Adimab, LLC | In force | High confidence | |
| US 11,398,771 | Switching Regulator Control Circuit Enabling Fault Protection Operation, Current-Mode-Control Switching Power Supply Device, and Vehicle In force · Medium confidence | Compass Therapeutics LLC | In force | Medium confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by Adimab, LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.